Trevi Therapeutics Inc
TRVIHealthcare|Biotechnology|USA
$17.84
-0.56 (-3.02%)
Tangible Book
$1.34
Earnings Power
$1.16
Upcoming Data Readouts (2)
Sep 2027
Est. completion
P2Refractory Chronic Cough
The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)
NCT07671924n=100
Jun 2028
Est. completion
P3Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
NCT07671911n=306